Financials data is unavailable for this security.
View more
Year on year Vitrolife AB had net income fall from a gain of 394.00m to a loss of 3.85bn despite a 8.60% increase in revenues from 3.23bn to 3.51bn.
Gross margin | 58.16% |
---|---|
Net profit margin | -107.03% |
Operating margin | -100.06% |
Return on assets | -19.99% |
---|---|
Return on equity | -24.90% |
Return on investment | -20.71% |
More ▼
Cash flow in SEKView more
In 2023, Vitrolife AB increased its cash reserves by 48.96%, or 283.00m. The company earned 757.00m from its operations for a Cash Flow Margin of 21.55%. In addition the company used 124.00m on investing activities and also paid 300.00m in financing cash flows.
Cash flow per share | -24.84 |
---|---|
Price/Cash flow per share | -- |
Book value per share | 97.03 |
---|---|
Tangible book value per share | -7.67 |
More ▼
Balance sheet in SEKView more
Current ratio | 2.91 |
---|---|
Quick ratio | 2.36 |
Total debt/total equity | 0.156 |
---|---|
Total debt/total capital | 0.135 |
More ▼
Growth rates in SEK
SmartText is unavailable
Div yield(5 year avg) | 0.25% |
---|---|
Div growth rate (5 year) | 3.30% |
Payout ratio (TTM) | -- |
EPS growth(5 years) | -- |
---|---|
EPS (TTM) vs TTM 1 year ago | -1,046.56 |
More ▼